ABSTRACT
No disponible
Subject(s)
Adult , Humans , Male , Imaging, Three-Dimensional/instrumentation , Imaging, Three-Dimensional/methods , Vascular Malformations/blood , Vascular Malformations/genetics , Skin Neoplasms/congenital , Skin Neoplasms/genetics , Endothelial Cells/cytology , Nevus/genetics , Imaging, Three-Dimensional/standards , Imaging, Three-Dimensional , Vascular Malformations/complications , Vascular Malformations/metabolism , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Endothelial Cells/metabolism , Nevus/pathologySubject(s)
Gastrointestinal Neoplasms/pathology , Nevus, Blue/pathology , Skin Neoplasms/pathology , Aged , Humans , MaleABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Dermatitis Herpetiformis/pathology , Autoantibodies/immunology , Autoantigens/immunology , Biopsy , Combined Modality Therapy , Dapsone/therapeutic use , Dermatitis Herpetiformis/diagnosis , Dermatitis Herpetiformis/immunology , Dermatitis Herpetiformis/therapy , Diet, Gluten-Free , Fluorescent Antibody Technique, IndirectABSTRACT
Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and has been approved for the treatment of rheumatoid arthritis (RA) patients who have had an inadequate response to previous biological therapies. Psoriasiform skin lesions, especially palmoplantar pustulosis lesions, are well described following anti-tumour necrosis factor therapy. We describe a 79-year-old woman with rheumatoid factor-positive, anti-citrullinated protein antibody-positive erosive RA, who developed a psoriasiform palmoplantar pustulosis reaction following treatment with TCZ therapy (IL-6 receptor). The rash showed histological features compatible with psoriasis and disappeared following discontinuation of TCZ.